gabexate has been researched along with Shock in 8 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of gabexate-mesilate (FOY) in circulatory shock in man." | 9.07 | [Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study]. ( Innocenti, P; Livi, P; Novelli, GP, 1993) |
| "To evaluate the efficacy of gabexate-mesilate (FOY) in circulatory shock in man." | 5.07 | [Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study]. ( Innocenti, P; Livi, P; Novelli, GP, 1993) |
| "Protease inhibitors, such as ulinastatin and gabexate mesilate, are widely used for the patients in shock state." | 3.67 | [The effect of protease inhibitors in shock]. ( Endo, Y; Inoue, H; Miura, J; Motoki, R; Terashima, S; Usuba, A; Watanabe, M, 1989) |
| "The effect of the epsilon-guanidino acid derivate camostate (FOY 305) on lipolysis of isolated adipocytes was evaluated to test its supposed influence on the reactions of lipid metabolism in experimental shock." | 3.67 | Influence of a low molecular weight serine proteinase inhibitor (camostate) on lipolysis of isolated adipocytes. ( Göke, B; Göke, R; Lankisch, PG, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyazaki, M | 1 |
| Yoda, K | 1 |
| Ogli, K | 1 |
| Yokono, S | 1 |
| Novelli, GP | 1 |
| Innocenti, P | 1 |
| Livi, P | 1 |
| Mitsuoka, H | 1 |
| Kistler, EB | 1 |
| Schmid-Schönbein, GW | 1 |
| Kashima, K | 1 |
| Kataoka, K | 1 |
| Umehara, K | 1 |
| Motoki, R | 2 |
| Inoue, H | 2 |
| Usuba, A | 1 |
| Endo, Y | 1 |
| Terashima, S | 1 |
| Watanabe, M | 1 |
| Miura, J | 1 |
| Schlag, G | 1 |
| Redl, H | 1 |
| Göke, B | 1 |
| Göke, R | 1 |
| Lankisch, PG | 1 |
1 trial available for gabexate and Shock
| Article | Year |
|---|---|
[Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study].
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Gabexate; Humans; Italy; Male; Middle Aged; Shoc | 1993 |
7 other studies available for gabexate and Shock
| Article | Year |
|---|---|
[Problems in the use of newly introduced anti-shock agents].
Topics: Adrenal Cortex Hormones; Animals; Benzamidines; Complement Inactivator Proteins; Gabexate; Guanidine | 1983 |
Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock.
Topics: Animals; Blood Pressure; Endopeptidases; Esters; Gabexate; Guanidines; Humans; In Vitro Techniques; | 2002 |
[Treatment of acute pancreatitis].
Topics: Acute Disease; Benzamidines; Disseminated Intravascular Coagulation; Drainage; Gabexate; Glycoprotei | 1992 |
[Protease inhibitors in shock].
Topics: Aprotinin; Disseminated Intravascular Coagulation; Gabexate; Glycoproteins; Humans; Infant, Newborn; | 1991 |
[The effect of protease inhibitors in shock].
Topics: Animals; Blood Coagulation Disorders; Dogs; Gabexate; Glycoproteins; Guanidines; Humans; Kidney; Ser | 1989 |
The proteinases in shock.
Topics: Blood Coagulation; Endopeptidases; Fibrinolysis; Gabexate; Granulocytes; Guanidines; Humans; Kallikr | 1986 |
Influence of a low molecular weight serine proteinase inhibitor (camostate) on lipolysis of isolated adipocytes.
Topics: Adipose Tissue; Animals; Esters; Gabexate; Guanidines; Lipolysis; Male; Rats; Rats, Inbred Strains; | 1985 |